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Abstract
Background: The isozymes of alkaline phosphatase, the tissue non-specific, intestinal and placental, have
similar properties and a high degree of identity. The placental isozyme (PLAP) is an oncofetal antigen
expressed in several malignancies including choriocarcinoma, seminoma and ovarian carcinoma. We had
earlier attempted to isolate PLAP-specific scFv from a synthetic human immunoglobulin library but were
unable to do so, presumably because of the similarity between the isozymes.
In this work, we have employed a PLAP-specific uncompetitive inhibitor, L-Phe-Gly-Gly, to select isozyme
specific scFvs. An uncompetitive inhibitor binds to the enzyme in the presence of substrate and stabilizes
the enzyme-substrate complex. Several uncompetitive inhibitors have varying degrees of isozyme
specificity for human alkaline phosphatase isozymes. A specific uncompetitive inhibitor would be able to
unmask conformational differences between the otherwise very similar molecules. Also, such inhibitors
would be directed to regions at/close to the active site of the enzyme. In this work, the library was first
incubated with PLAP and the bound clones then eluted by incubation with L-Phe-Gly-Gly along with the
substrate, para-nitro phenyl phosphate (pNPP). The scFvs were then studied with regard to the
biochemical modulation of their binding, isozyme specificity and effect on enzyme activity.
Results: Of 13 clones studied initially, the binding of 9 was inhibited by L-Phe-Gly-Gly (with pNPP) and 2
clones were inhibited by pNPP alone. Two clones had absolute and 2 clones had partial specificity to PLAP.
Two clones were cross-reactive with only one other isozyme. Three scFv clones, having an accessible
His6-tag, were purified and studied for their modulation of enzyme activity. All the three scFvs inhibited
PLAP activity with the kinetics of competitive inhibition. Cell ELISA could demonstrate binding of the
specific scFvs to the cell surface expressed PLAP.
Conclusion: The results demonstrate the biochemical modulation of scFv binding. Also, the scFvs bound
to the active site and denied the access to the substrate. The selection strategy could generate specific
anti-enzyme antibodies to PLAP that can potentially be used for targeting, for modulating enzyme activity
in in vitro and in vivo and as probes for the active site. This strategy also has a general application in selecting
antibodies from combinatorial libraries to closely related molecules and conformations.
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The alkaline phosphatases (APs) are a family of enzymes
with a number of isozymes and isoforms that differ from
each other in various degrees of amino acid sequences and
the extent and nature of glycosylation. In humans, three
of the four AP isozymes aretissue specific, i.e., the intesti-
nal AP (IAP), placental AP (PLAP), and germ cell AP
(GCAP), while the fourth AP gene is the tissue-nonspeci-
ficAP (TNAP) found expressed in bone, liver, and kidney
[1]. There is 50% identity between TNAP and PLAP and
86% identity between Intestinal and Placental isozyme at
the level of protein sequence [2-5]. In this study, TNAP is
represented by bone isozyme (BAP). The postulated func-
tions of the isozymes are many [6-8]. While the ubiqui-
tous expression of AP family across the phyla and also
within the human body points to a broad conservation of
important functions, the diversity of the isozymes and iso-
forms also indicates a certain degree of differentiation and
specificity regarding their functions.
Our laboratory has been working on the generation of
recombinant antibodies to PLAP for possible use in tumor
targeting [9,10]. PLAP is expressed on the cell surface in
several types of malignancies [11], including choriocarci-
nomas, seminomas, and tumors of ovary, uterus, cervix,
breast, lung, stomach and bladder. Even though the per-
centage expression in a particular tumor type is variable,
the total numbers of tumors expressing the antigen are
quite high, and encompass a range of solid tumors. Most
Polyclonal MBPhEFigure 2
Polyclonal MBPhE. 1011 pfu of each round phage eluted with L-Phe-Gly-Gly + pNPP were checked for binding affinity to 
PLAP-conjugated magnetic beads (solid bars) against the background binding of phage to the unconjugated beads (white bars). 
The black bars on top indicate SD.
Flow Chart of the selection strategyigure 1
Flow Chart of the selection strategy.Page 2 of 13
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have a poor outcome. Certain characteristics of PLAP, like
cell surface localization [12], clathrin mediated endocyto-
sis [13] and low shedding into circulation makes it an
ideal target for immunolocalization and immunotherapy
[14]. Antibodies specific to PLAP would be useful for
localizing therapeutic modalities like conjugated toxins,
drugs and liposomes carrying cytotoxic compounds as
well as for tumor imaging. In our earlier work [9,10], we
had attempted to select phage clones exhibiting isozyme
specific binding from a phage-displayed human scFv
library [15]. As is usually done, we had selected anti-PLAP
scFv by allowing the phage library to bind to immobilized
PLAP and eluted with high pH. Though we could select
clones that bound the selecting antigen, we failed to iso-
late PLAP-specific clones. This highlighted the need for
adopting alternative strategies for isolating phage anti-
bodies that bind to defined structural regions in an iso-
zyme specific manner.
It would be a rational strategy to use small molecules that
bind to defined regions of the selecting antigen to elute
out bound phage from specific antigenic conformations.
For enzymes in general, the detailed studies on substrates
and inhibitors available in literature suggest ways for car-
rying out such selections. There are several aspects of the
catalysis by AP family that offer clues to conformations
that could be exploited for the selective targeting of the
isozymes. While all of the isozymes can catalyse several
small molecular artificial substrates (like pNPP), even
within the isozymes expressed in human tissues there are
several uncompetitive inhibitors that have varying degrees
of isozyme specificity. L-Phe-Gly-Gly and L-Leu are PLAP-
specific, while L-Phe inhibits both PLAP and IAP [16]. L-
Homoarginine specifically inhibits TNAP [16]. The bind-
ing patterns of these inhibitors perhaps reflect homolo-
gies or unique structures in these molecules [16,17]. An
uncompetitive inhibitor is effective only in the presence of
substrate [16]. Uncompetitive inhibitors bind to the
enzyme-substrate complex and their binding site would
therefore be at/close to the active site of the enzyme
[18,19]. It was expected that L-Phe-Gly-Gly (along with
pNPP) would; therefore, elute phage bound to the defi-
nite structures on PLAP that were unique to the isozyme.
Such a strategy would also provide a way for the directed
selection of isozyme specific phage antibodies. X-ray crys-
tallography has revealed that the active site of PLAP is a
large shallow depression [20]. Therefore, it would be pos-
sible for such scFvs to interact directly with the active site
and also modulate PLAP function.
In this study, we have incubated the phage-displayed scFv
library with PLAP and eluted the phage clones bound to
the immobilized PLAP by L-Phe-Gly-Gly in the presence
of pNPP. These clones have been studied with regard to
their isozyme specificity, biochemical modulation of
binding and the effect of their binding on the enzyme
activity. This strategy has enabled us to isolate a high pro-
portion of scFv antibodies that are isozyme specific and
bind to the active site, as evidenced by the modulation of
enzyme activity. The binding characteristics of these
phage antibodies provide useful information regarding
the conformational relatedness of the AP isozymes and
thus could also serve as structural probes.
Results
Selection of PLAP binding clones and determination of 
antigen binding
The pH of 9.6, which is optimal for PLAP activity, would
probably denature the scFv displayed on the phage and
also disrupt PLAP-scFv interaction. Hence, after standard-
ization, a pH of 8.0 was chosen for elution with 0.01 M L-
Phe-Gly-Gly. At this pH, PLAP activity was retained and
the enzyme activity was inhibited by L-Phe-Gly-Gly but
not by the control peptide L-Gly-Gly-Gly. Phage eluted by
L-Phe-Gly-Gly + pNPP (Figure 1), were amplified after
Table 1: Transforming units (TUs) of PLAP binding phage. Transforming units (TUs) of PLAP binding phage after each round of 
selection. There was an initial fall in the TUs of the eluted phage in comparison to the input phage. There was also a decrease in the 
TUs of the phage eluted after the second round of selection indicating the decrease in phage binding non-specifically to the beads. For 
the rounds one and two, the selection was carried out on magnetic beads. For the rounds three and four, the selection was carried out 
on immunotubes.
Rounds of selection Transforming units (input) Transforming units eluted 
with pNPP (output)
Transforming units eluted 
with L-Phe-gly-gly + pNPP 
(output)
Unselected library 1014 - -
First 1014 102 1012
Second (PLAP- conjugated beads 
were reduced)
1014 THIS STEP WAS NOT 
PERFORMED FOR THE SECOND 
ROUND OF SELECTION
109
Third (selection on Immunotubes) 1014 106 104
Fourth (selection on 
Immunotubes)
1014 107 106Page 3 of 13
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was assessed by Magnetic Bead Phage ELISA (MBPhE).
The fourth round phage showed significant binding to
PLAP (Figure 2). Hence, individual phage clones from the
fourth round were assessed for their ability to bind PLAP.
Enrichment in Transforming units (TUs) of PLAP binding 
phage after each round of selection
The Transforming Units (TUs) of input and output phage
after each round of selection are shown in Table 1. There
was an initial fall in the TUs of the eluted phage in com-
parison to the input phage. Also, we observed a decrease
in the TUs of the phage eluted after the second round of
selection indicating the decrease in phage binding non-
specifically to beads. There was an increase in phage TUs
in subsequent rounds of selection indicating enrichment
of selected anti-PLAP phage.
Antigen binding characteristics of monoclonal anti-PLAP 
scFvs
100 phage clones from the fourth round of selection were
assessed for PLAP binding by MBPhE. This was performed
like the polyclonal MBPhE. 30 PLAP binding clones were
detected (Figure 3). Out of these, 13 clones were selected
on the basis of extent of binding and were further charac-
terized.
Magnetic Bead Phage ELISA (MBPhE) in the presence of 
inhibitors
This was done for the 13 clones that gave significant bind-
ing to PLAP. Binding was studied in the presence of the
inhibitor L-Phe-Gly-Gly or the control peptide L-Gly-Gly-
Gly along with the substrate pNPP. Based on the inhibi-
tion of antigen binding by substrate and L-Phe-Gly-Gly/L-
Gly-Gly-Gly, these clones were of three types. Type I (Fig-
ure 4A) comprised of the clones whose binding was inhib-
ited by L-Phe-Gly-Gly but not by L-Gly-Gly-Gly (9 clones
were of this type including the clones GLE4 and GL2D).
This indicated that the bound clones were displaced from
PLAP on the formation of the enzyme-substrate-inhibitor
complex. Type II phage antibodies (Figure 4B) comprised
of 2 clones whose binding was inhibited by substrate
alone (clones GLD6 and GLA12). The inhibitor, L-Phe-
Gly-Gly or the control peptide L-Gly-Gly-Gly did not
affect the binding. This suggested that while the clone was
displaced on the binding of the substrate PLAP, the inhib-
itor did not influence the binding. Type III phage antibod-
ies (Figure 4C) comprised of 2 clones whose binding was
not inhibited by either L-Phe-Gly-Gly or L-Gly-Gly-Gly
(clones GLA5 and GLA8). The binding of these clones was
not inhibited by either substrate or inhibitor and sug-
gested that their elution was presumably physico-chemi-
cal.
PLAP binding activity of the 30 phage clones (of the 100 tested) that showed positive binding in the Magnetic Bead Phage ELISAFigure 3
PLAP binding activity of the 30 phage clones (of the 100 tested) that showed positive binding in the Magnetic 
Bead Phage ELISA. The solid bars represent binding of the each phage clone to the PLAP-conjugated magnetic beads. The 
empty bars represent binding activity of phage clones to the unconjugated magnetic beads (negative control).Page 4 of 13
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phosphatase
The binding of scFvs to biotinylated-PLAP was competed
with the increasing molar concentrations of unbioti-
nylated PLAP, IAP or BAP. The binding of the studied
clones to biotinylated-PLAP was affected in the presence
of unbiotinylated soluble isozymes (PLAP, BAP, IAP) to a
different extent, depending on the clone. The binding of
two clones (clones GLE4 and GL2D) to biotinylated-PLAP
was inhibited only by unbiotinylated PLAP and not the
other two isozymes of alkaline phosphatase (Figure 5A).
The binding of two clones was inhibited by unbioti-
nylated PLAP at much lower molar concentrations than
by the other two isozymes. This indicated that selection
strategy led to the preferential isolation of PLAP-specific
scFvs. For 3 clones (including clone GLD6) binding to
biotinylated-PLAP was inhibited in the presence of two
isozymes (BAP and PLAP) but not the third (Figure 5B).
However, seven clones (including clone GLA8) exhibited
inhibition of binding to biotinylated-PLAP in the pres-
ence of all the three isozymes of alkaline phosphatase
(Figure 5C).
Binding features of Type I, Type II and Type III antibodies on MBPhEF gure 4
Binding features of Type I, Type II and Type III antibodies on MBPhE. 4A. Representative binding of Type I antibodies on 
MBPhE. The binding of these antibodies was inhibited by L-Phe-Gly-Gly + pNPP but not by L-Gly-Gly-Gly + pNPP. The uncon-
jugated magnetic beads served as a negative control. The black bars on top indicate SD. 4B. Representative binding of Type II 
antibodies on MBPhE. The binding of these antibodies was inhibited both by L-Phe-Gly-Gly + pNPP and L-Gly-Gly-Gly + pNPP 
and by substrate alone. The unconjugated magnetic beads served as a negative control. The black bars on top indicate SD. 4C. 
Representative binding of Type III antibodies on MBPhE. The binding of these antibodies was not inhibited by L-Phe-Gly-Gly + 
pNPP or L-Gly-Gly-Gly + pNPP. The unconjugated magnetic beads served as a negative control. The black bars on top indicate 
SD.Page 5 of 13
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activity
Three scFv antibodies, GLE4, GLD6 and GL2D, had an
accessible His6-tag and were purified on metal affinity col-
umns. There is also a possibility that the His-tag was not
detectable in the other clones because of their poor
expression levels, but this has not been explored further.
The ability of the three selected clones to modulate the
activity of the three isozymes, PLAP, IAP and BAP was
studied in detail. Clones GLE4 and GL2D specifically
inhibited the activity of PLAP but not of the other iso-
zymes (IAP and BAP). Clone GLD6, that binds to both
PLAP and BAP, inhibited the activity of these two iso-
zymes but not of IAP. The nature of inhibition of PLAP
Characteristics of PLAP-scFv binding in the presence of competing isozymesFigure 5
Characteristics of PLAP-scFv binding in the presence of competing isozymes. 5A. A fixed amount of biotinylated-PLAP 
was incubated with immobilized soluble scFv of the clone GLE4. The extent to which this could be inhibited by varying concen-
trations of competing isozymes was measured. Binding in the absence of any competing isozyme was taken as 100%. The bind-
ing to biotinylated-PLAP is inhibited only by unbiotinylated PLAP and not the other two isozymes of alkaline phosphatase. The 
labels on x-axis represent the molar concentration of the various isozymes included in the experiment. 5B. Competition of 
PLAP-GLD6 binding by IAP and BAP. Normalisation of the data was done as in Figure 6A. The binding to biotinylated-PLAP is 
inhibited by the two isozymes (BAP and PLAP) but not the third. The labels on x-axis represent the molar concentration of the 
various isozymes included in the experiment. 5C. Competition of PLAP-GL2D binding by IAP and BAP. Normalisation of the 
data was done as in Figure 6A. Binding to biotinylated-PLAP binding was inhibited by all the isozymes of alkaline phosphatase. At 
the maximum concentration of competing isozyme studied, the inhibition was the same. However, there was a slight difference 
in the relative affinity when 50 % inhibition was calculated. The labels on x-axis represent the molar concentration of the vari-
ous isozymes included in the experiment.Page 6 of 13
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substrate concentrations. Lineweaver-Burk (1/V vs. 1/[S])
plots were made for GLE4, GL2D and GLD6 (Figures 6, 7
and 8respectively). All the mentioned scFv clones inhibited
enzyme activity. The plots in the presence of the scFvs sug-
gested a competitive type of inhibition as the inhibition
was completely relieved by higher concentrations of the
substrate, indicating competition by the antibody and
substrate for a site on the PLAP molecule. For the Clone
GLE4, Km of the enzyme was 5.55 mM; Enzyme with scFv:
K'm: 11.11 mM and Ki ~108 M-1. For the Clone GLD6, Km
of the enzyme was 5.55 mM; Enzyme with scFv: K'm: 15
mM and Ki ~109 M-1. For the Clone GL2D, Km of the
enzyme was 5.55 mM; Enzyme with scFv: K'm: 25 mM
and Ki ~108 M-1.
Binding of the purified scFvs to PLAP expressed on tumor 
cell lines
The two scFv clones, E4 and GL2D, showed binding to the
purified PLAP in an isozyme specific manner. The binding
of these scFvs was then studied on HeLa cell line that is
known to express PLAP. Cell ELISA could detect binding
of these two clones in a PLAP-specific manner. Both the
clones showed binding to PLAP expressed on HeLa cells
(Figure 9).
Lineweaver-Burk Plot of inhibition of PLAP activity by purified GLE4Figur  6
Lineweaver-Burk Plot of inhibition of PLAP activity by purified GLE4. The enzyme activity of PLAP is inhibited in a com-
petitive manner. Km of the enzyme: 5.5 mM; Km of the enzyme with GLE4: 40 mM. Inset shows % inhibition of enzyme activity 
by varying amount of purified scFv GLE4 (This clone also shows a higher binding [by ELISA] to PLAP as compared to BAP or 
IAP).Page 7 of 13
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Identity analysis of the scFv sequences was performed at
NCBI BLAST server. The sequences showed identity to
immunoglobulin heavy and light chain variable frag-
ments. The sequences of the selected clones have been
submitted to EMBL and their accession numbers are as
follows: clone GLE4-AJ704539, clone GL2D- AJ704837
and cloneGLD6-AJ704834. The germline origin of all the
sequences were determined using DNAPlot at the VBASE
database and the data is shown in Table 2. All the
sequences were numbered as per Kabat convention. No
domain deletion or frame shifts were observed in these
sequences.
Discussion
Various selection strategies for phage-displayed antibod-
ies have been described, especially for large combinatorial
libraries with high degrees of diversity. The selection strat-
egy is very important in determining the binding charac-
teristics of the phage [21]. The implementation of specific
biochemical methods of selection, wherever possible,
would give the selected phage a certain degree of pre-
determined epitope specificity. In the case of human alka-
line phosphatases a unique panel of uncompetitive inhib-
itors permits the distinction between the various
isozymes, in spite of their having a high degree of
sequence identity. In this work, phage antibodies were
eluted with a PLAP-specific uncompetitive inhibitor, L-
Phe-Gly-Gly, in the presence of substrate, to select clones
that are likely to be isozyme specific. By definition, an
uncompetitive inhibitor binds to the enzyme-substrate
complex and hence would be likely to bind close to the
active site of the enzyme.
Our selection strategy entailed the use of optimal pH for
phage viability and enzyme inhibition. We have used
alternating surfaces of magnetic beads and plastic immu-
notubes to avoid selection of phage binding to the solid
support. The fourth round polyclonal phage showed sig-
nificant binding to PLAP. Next, the binding of mono-
clonal scFvs was studied in the presence of L-Phe-Gly-Gly
or L-Gly-Gly-Gly (along with the substrate, pNPP). For
Lineweaver-Burk Plot of inhibition of PLAP activity by purified GL2DFigur  7
Lineweaver-Burk Plot of inhibition of PLAP activity by purified GL2D. The enzyme activity of PLAP is inhibited in a com-
petitive manner. Km of the enzyme: 5.5 mM; Km of the enzyme with GL2D: 25 mM. Inset shows % inhibition of enzyme activity 
by varying amount of purified scFv GL2D (This clone also shows a higher binding [by ELISA] to PLAP as compared to BAP or 
IAP).Page 8 of 13
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Phe-Gly-Gly + substrate, indicating that they bound to a
region of PLAP from where they were displaced by the spe-
cific inhibitor. Of the three clone studied in detail (Clones
GL2D, GLE4 and GLD6), two (GL2D and GLE4) were of
Type I. They bound only to PLAP. However, for two clones
(GLD6 and GLA12), the substrate (pNPP) alone was suf-
ficient to displace the bound scFv, indicating their binding
to the active site of the enzyme. Since the synthetic sub-
strate is common to all the three isozymes, the conforma-
tion of the binding site for such clones is likely to be a
shared one. One such clone (GLD6) has been studied in
detail. This was cross-reactive with BAP but not with IAP.
This is interesting because PLAP has a greater overall sim-
ilarity with IAP than with BAP. It is probable that the dis-
placed scFv made contact with those conformations of
PLAP that were shared with BAP but not IAP.
The modulation of enzyme activity by the purified scFvs
reflected that the selection strategy was targeted towards
the active site of PLAP. All the three clones inhibited the
activity of the bound isozyme. In all the cases, the inhibi-
tion was completely relieved by excess substrate indicat-
ing competition for the same binding site. The Alkaline
Phosphatase structure reveals five crucial regions, namely
theactive site and its vicinity, the active site valley, the
homodimerinterface, the crown domain, and the metal-
binding site [20]. The active site is a shallow groove, sug-
gesting that phospho-proteins could be natural substrates
for alkaline phosphatase in vivo. The modulation of
enzyme activity by the scFv would support the notion of
an active site accessible to large molecules. The soluble
scFv, when it bound to the enzyme, presumably denies
the substrate access to the active site. The asymmetry of
the molecular weights of pNPP and scFv is also worth not-
ing. The scFv, being a large molecule, cannot form a
bridge between the enzyme-substrate complex and the
crown and acts as a competitive inhibitor possibly by
extruding the substrate from the active site.
The crown domain and the metal-binding domain are
mammalian-specific andwere observed for the first time
in the PLAP structure. The domain is said to be involved
in the properties of the enzyme that distinguish one iso-
zyme form the other [22]. The binding of uncompetitive
inhibitors like L-Phe and L-Leu have been studied and
Lineweaver-Burk Plot of inhibition of PLAP activity by purified GLD6Figur  8
Lineweaver-Burk Plot of inhibition of PLAP activity by purified GLD6. The enzyme activity of PLAP is inhibited in a com-
petitive manner. Km of the enzyme: 5.5 mM; Km of the enzyme with GLD6: 15 mM. Inset shows % inhibition of enzyme activity 
by varying amount of purified scFv GLD6 (This clone has a higher binding [by ELISA] to PLAP and BAP as compared to IAP).Page 9 of 13
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PLAP and IAP. The inhibitor acts by functionally interact-
ing with Arg 166 and Zn2+ ion through its carboxy and
amino groups respectively, and the conformation of the
unique surface loop located in the vicinity of the active
site influences both the positioning of the inhibitor and
its accessibility to the active site [24]. Mutations of PLAP
at residue 367 with Ala and Phe, as well as the correspond-
ing double mutants containing Gly 429 have been shown
to result in a 2-fold decrease in kcat, a significant decrease
in heat stability, and disruption of inhibition by the
uncompetitive inhibitors L-Phe and L-Leu [23]. Because
the crystal structure has only been elucidated for the bind-
ing of L-Phe to PLAP, such antibody probes would be use-
ful for further exploring the binding of these inhibitors.
While the binding of L-Phe-Gly-Gly has not been so exten-
sively studied, the site is probably overlapping but not
identical to that of L-Leu. The binding sites of L-Leu and
L-Phe-Gly-Gly are probably located close to each other
but may not be identical [24].
The present study demonstrates that isozyme specific
inhibitors can be used to select phage antibodies that in
many cases, bind to the active site and show isozyme spe-
cificity. Such molecules can distinguish similar conforma-
tions and therefore, possibly act as structural probes. In
addition, antibodies that inhibit enzyme activity and bind
to the cell surface expressed PLAP, could be employed to
study the physiological and pathological significance of
PLAP, and for targeting tumour cells. In a more general
way, the study highlights how the specificity of small mol-
ecules can be utilized to select binding entities directed to
the specific molecular regions from large and highly
diverse combinatorial libraries.
Conclusion
The results indicate that a small molecule inhibitor can be
used to select phage antibodies directed to the active site
of PLAP. The binding of most of the scFvs selected by this
process was reduced in the presence of the inhibitor. A sig-
nificant number of clones had various degrees of isozyme
specificity. The three clones studied showed inhibition of
enzyme activity, suggesting that they bound to the active
site and denied the access to the substrate. This indicated
the success of the selection strategy. The specific clones
showed binding to HeLa cells (that express PLAP). These
scFvs could thus be used as probes for the active site of
PLAP and to modulate enzyme activity. This strategy also
has a general application in selecting specific antibodies
from combinatorial libraries to closely related molecules
and conformations.
Methods
General reagents – Acetic acid, Ammonium acetate, Chlo-
roform, Disodium hydrogen phosphate, Glycerol, Gly-
cine, Hydrochloric acid, Isopropyl alcohol, Isoamyl
alcohol, Methanol, Potassium acetate, Sulphuric acid,
Sodium chloride, (AR grade) – SRL, India or Qualigens,
India. 8-Hydroxy quinoline, Acryl amide, Ammonium
persulphate (APS), Ampicillin, Bis – Acryl amide, Dextran
sulphate, Disodium ethylene diamine tetra acetate
(EDTA), Isopropyl thio-β-D-galacto pyranoside (IPTG),
Kanamycin, Lysozyme, Magnesium chloride, N,N,N,N'-
tetramethylethylenediamine (TEMED), Phenol, Sodium
lauryl sulphate (SDS), – Sigma Chemical Co., St. Louis, USA
or US Biochemicals, USA or SRL, India or BDH, England.
Media components – Bacto – agar, Yeast extract, Tryptone,
Tissue – culture media; sodium bicarbonate; trypsin –
Sigma Chemicals Co., USA. Amino acids and proteins – L-
Leucine, L-Phe, L-Phe-Gly-Gly, L-Gly-Gly-Gly, L-
Homoarginine and Placental alkaline phosphatase, Bone
Table 2: Germline origin of all the sequences.
Clone Germline V sequences
EMBL Accession number Heavy Chain (VH) Light Chain (VL)
Clone GLE4 AJ704539 1-02 (Z14071) L11 (X93621)
Clone GL2D AJ704837 ** 7a (Z73659)
Clone GLB10 AJ704836 4-30.2 (Z12364) 1e (Z22193)
Clone GL5D AJ704835 4-59 (Z12371) 9a (Z73675)
Clone GL D6 AJ704834 1-12 (M99638) 1a (Z73653)
Clone GL B6 AJ704538 6-01 (Z12374) O11/O1 (X93631)
Clone GL A5 AJ704537 1-02 (Z14071) 1g (Z73663)
Clone GL C4 AJ704536 1-02 (Z14071) 1e (Z73656)
Clone GL D5 AJ704535 4-b (M12071) L12 (X72813)
Clone GL G11 AJ704532 4-30.4 (Z14074) 1g (Z73663)
Clone GL A8 AJ704533 1-02 (Z14071) 1g (Z73663)
Clone GL A12 AJ704534 4-61 (Z12366) L12 (X72813)
**Insert size of the clone GL2D is 750 bp and there are segments missing in the heavy chain, making it difficult to attribute a matching germline 
sequence. However, the remaining portions of the heavy chain confirm its identity as part of heavy chain.Page 10 of 13
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Sigma Chemicals Co., USA and Calzyme Inc., USA. Enzymes
– Taq DNA polymerase, SfiI and NotI – Bangalore Genei,
India. Blotting Membranes And Filters – Nitrocellulose
(.45 µm) and 3 M blotting sheets – Schleicher and Schull,
Germany and Whatman, USA. Kits And Systems-Biotinyla-
tion kit, Sigma Chemicals Co., USA; Bacterial Strains – E.
coli HB2151 from MRC, Cambridge/Pharmacia, USA; E. coli
XL-1 blue MRF' from Stratagene, USA. Cell lines – HeLa
cell lines from lab collection.
Description of the library
The Griffin.1 library is a 'scFv' phagemid library made
from synthetic V-gene segments. The library was con-
structed by re-cloning the heavy and light chain variable
regions from the lox library vectors into the phagemid vec-
tor pHEN2 [15].
Phage rescue, precipitation and titration
The phage propagation steps were performed as described
in Kala et al [9].
Immobilization of PLAP antigen
PLAP (Sigma Chemical Co., USA) was covalently conju-
gated to carboxy-terminal magnetic beads using 1-ethyl-3-
(3-diethylaminopropyl) carbodiimide (EDCI) as the cou-
pling agent according to the manufacturer's protocol and
percentage coupling was determined on the basis of
absorption of pre and post coupling PLAP solution. These
PLAP-conjugated beads were used for selection of PLAP
binding phage from the synthetic immunoglobulin
library.
Panning strategy
Figure 1 summarizes the methodology employed for pan-
ning. We observed that incubation of PLAP with 0.01 M L-
Phe-Gly-Gly along with 4 mg/ml pNPP substrate at pH
8.0 resulted in inhibition of enzyme activity without
affecting phage viability and scFv binding. Hence these
conditions were used during panning and isolation of
phage clones.
500 µl of PLAP conjugated beads (~100 µg PLAP) and 500
µl unconjugated beads were blocked with 2 % MPBS
(non-fat milk PBS) for 2 hours at 37°C. After washing the
unconjugated beads with PBS, these were incubated with
1 ml phage (TU ~1013) in 2 % MPBS for 30 min on a
rocker to reduce non-specific binding. The unbound
phage were added to the blocked PLAP- conjugated beads,
incubated for 30 minutes on a rotating turntable and then
kept static at room temperature (RT) for 90 minutes. After
removing unbound phage, the beads were washed 10
times with PBS-Tween (0.05 %) (PBST) followed by 10
washes with PBS. Bound phage were eluted with 1 ml of
the substrate, pNPP (4 mg/ml in PBS), for 30 min at RT.
This was done in order to elute phage that were directly
displaced by the substrate alone. As the substrate was
common to all the isozymes, such phage would be more
likely to bind to conformations common to all isozymes.
After removing these eluted phage, further elution was
done with 1 ml of 0.01 M L-Phe-Gly-Gly (inhibitor pep-
tide) solution in PBS containing 4 mg/ml pNPP. The
eluted phage were infected into exponentially growing
culture of E. coli TG1 and plated on large agar/amp dishes
for overnight at 37°C. Stocks of selected phage were made
by scraping the dishes with 15 % glycerol in 2xTY. Phage
from these stocks were amplified for further rounds of
selection. In the second round of panning, the volume of
PLAP conjugated beads were reduced to 250 µl. and the
initial substrate (pNPP) elution step was not performed.
Elution was only by a combination of L-Phe-Gly-Gly and
pNPP. In the third round of panning the immobilizing
surface was changed to immunotubes (Nunc), coated
with 400 µl/ml of PLAP in HCO3- buffer pH 9.5. This was
done to select against the phage binding non-specifically
to the immobilizing surface. Elution was first done with
pNPP alone and then L-Phe-Gly-Gly + pNPP. The fourth
round was similar to the third except that the immuno-
tubes were washed for 15 times with PBST and 15 times
with PBS. This stringent washing was a further precaution
against non-specific binding.
Stocks of polyclonal phage in E. coli TG1 were made after
each round of selection and Transforming Units (TUs)
were calculated for phage obtained after each elution to
evaluate enrichment of the PLAP binders. For monoclonal
phage, individual colonies obtained after the fourth
round were rescued and precipitated as described earlier.
Cell ELISA to study the binding of the isozyme specific scFvs to the cell surface expressed PLAPFigure 9
Cell ELISA to study the binding of the isozyme specific 
scFvs to the cell surface expressed PLAP. The two PLAP-
specific purified scFvs, clone E4 and clone GL2D showed sig-
nificant binding to the HeLa cells that express PLAP (solid 
bars). SaOs-2 cells, that do not express PLAP, served as con-
trol (empty bars). The scFv VB1 did not show binding to 
either of the cell types and served as a negative scFv control. 
The black bars on top indicate SD.Page 11 of 13
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displayed antibodies
i) Magnetic Bead Phage ELISA (MBPhE)
This was done essentially as described by Kala et al [9].
1011 TUs of either polyclonal or monoclonal phage were
incubated with 100 µl of PLAP conjugated beads (~15–
17.5 µg PLAP/100 µl beads). Binding was detected using
anti-M13 antibodies followed by anti-mouse-HRPO con-
jugate (Sigma USA).
ii) Inhibition of phage binding to PLAP by substrate and biochemical 
inhibitors
Uncompetitive inhibitor L-Phe-Gly-Gly or the negative
control L-Gly-Gly-Gly were added at the binding step of
the MBPhE at a final concentration of 0.01 M along with
substrate pNPP (final concentration of 4 mg/ml).
Sequencing of individual scFv clones
Individual scFv antibodies were analyzed for the presence
of scFv DNA insert by Not I- Sfi I digestion of the
phagemid DNA, PCR analysis and subsequent DNA
sequencing of the scFv insert. The sequencing primers
were pHEN-SEQ (5'CTATGCGGCCCCATTCA 3') and
LMB3 (5' CAGGAAACAGCTATGAC 3').
Expression of phage – displayed antibodies as soluble scFvs
The individual anti-PLAP monoclonal phage displayed
antibodies were infected into the non-suppressor strain of
E.coli HB2151 (OD600 ~0.5), and after IPTG induction, the
periplasmic fraction, containing the soluble scFv, was
used for further experiments. This was essentially done as
described in Kala et al [10].
Inhibition of PLAP-scFv binding by alkaline phosphatase 
isozymes
This was done in order to study the competition for the
PLAP binding of a scFv clone by equimolar concentrations
of the different alkaline phosphate isozymes (BAP and
IAP, Calzyme Laboratories Inc.) in comparison to the
inhibition resulting from PLAP itself. Firstly, the molar
concentration of biotinylated-PLAP giving 50 % binding
to scFv was determined. Next, this concentration of bioti-
nylated-PLAP for each scFv clone was used for the compe-
tition with soluble PLAP/IAP/BAP. The inhibition of the
binding of biotinylated-PLAP by different molar concen-
trations of BAP, IAP and PLAP was studied by including
them at the binding step of the ELISA.
Purification of scFv clones by metal affinity 
chromatography
Since the scFv clones expressed as a fusion protein with
His6 tag at the C – terminal, those having an accessible tag
were purified on a metal affinity column (Clontech Inc.,
USA) as per the manufacturer's instructions. The eluted
scFv was dialyzed against 50 mM Tris-NaCl buffer over-
night and resolved on a 15 % SDS-PAGE for the analysis
of its purity.
Influence of antibody binding on PLAP/IAP/BAP activity 
using pNPP as a substrate
This was done in order to determine if the binding anti-
body is a modulator of the enzyme activity. The effect on
the activity of PLAP, IAP and BAP was compared. This was
essentially performed in the following described steps.
Inhibition assay
0.01 µg of each of the isozymes was incubated with the
increasing amount of purified scFv antibody (0–100 µl)
and substrate pNPP (100 µl of the stock 4 mg/ml dis-
solved in Tris buffer, pH 9.0) for 1 hour at RT. The absorb-
ance was read at 405 nm. Percentage inhibition of the
activity of each of the isozymes by purified scFv antibodies
was plotted.
In the next experiment, the nature of inhibition of PLAP
activity by purified scFv antibodies was studied. The con-
centration of purified scFv antibodies exhibiting 50 %
inhibition of the enzyme activity was incubated with
increasing substrate concentrations (100 µl of the stock 1
mg/ml to 16 mg/ml, dissolved in Tris buffer, pH 9.0) for
15 minutes at 37°C and pH 9.0. The absorbance was read
at 405 nm and 1/V vs. 1/[S] curve was plotted. Also, the
calculation of Ki for each of the mentioned clones was
done using the following equation for tight-binding
inhibitors:
K'm = Km {1 + [I]/Ki} [25]
Cell ELISA to study binding of scFvs to the cell surface 
expressed PLAP
HeLa is a cervical carcinoma cell line known to express
PLAP. SaOs-2 is an osteosarcoma cell line that does not
express PLAP and is therefore, used as a negative control.
Tumor cell lines (HeLa and SaOs-2) were cultured in com-
plete medium in 96-well flat bottom plates (Corning) to
form a subconfluent monolayer and further incubated
overnight in DMEM medium containing 10% FBS. The
cells were washed 3 times for 5 min each with phosphate
buffered saline (PBS, pH 7.4) and cells were fixed by treat-
ment with 4% paraformaldehyde for 10 min at 4°C. The
endogenous peroxidase activity was blocked with 3%
H2O2 in distilled water for 7 min at room temperature fol-
lowed by 3 × 5 min washes in PBS, pH 7.4. Non-specific
binding was blocked with 3% bovine serum albumin
(BSA) for 1 h at room temperature. Cells were washed
once in PBS and incubated with purified scFvs (E4, GL2D
and VB1) diluted in 3%BSA for 2 h at room temperature.
After 3 × 10 min washes in PBS, mouse anti-His6 IgG anti-
body (diluted 1/1000 in 1% BSA-PBS) was added for 1
hour at room temperature. The cells were washed again inPage 12 of 13
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was added and incubated for 1 hour and the bound
enzyme activity was developed by adding OPD (5 mg/10
ml citrate buffer, pH 5.0) containing 5 µl of 30% H2O2.
The color reaction was stopped by adding 50 µl of 10%
H2SO4 and the intensity was read at 492 nm in a MicroE-
LISA reader.
The abbreviations used are
AP, alkaline phosphatase; BAP, bone alkaline phos-
phatase; DAB, di-aminobenzidine; EDCI, 1-ethyl-3-3-(-3-
diethylamonopropyl) carbodiimide; IAP, intestinal alka-
line phosphatase; IPTG, isopropylthiogalactosidase; mAb,
monoclonal antibody; MBPhE, Magnetic Bead Phage
ELISA; MPBS, milk in phosphate buffer saline; OPD,
ortho-phenylenediamine; PBS, phosphate buffer saline;
PLAP-placental alkaline phosphatase; pNPP, para nitro-
phenolphosphate; RT, room temperature; SD, Standard
Deviation ; TNAP-tissue non specific alkaline phos-
phatase.
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